XAGE1A (X Antigen Family Member 1A)

We also discuss the incorporation of CTA testing in lung cancer diagnostic workflows with focus on its analytical performance, preanalytical factors as well as comparative value vs existing markers. Finally, we outline the role of CTAs as companion diagnostics in immunotherapy and targeted treatment plans, and indicate the main challenges and research priorities towards the clinical translation of CTAs.

IL2RB, CENPB, TP53, and XAGE1A combined biomarker panel holds potential for rapid screening and could improve the diagnosis of early-stage LC, thus potentially also improving its prognosis.

The connection of high XAGE 1 level with advanced ovarian cancer stages has also been established, supporting XAGE 1's proposed role in poor prognosis. Finally, finding the specific involvement of this gene in ovarian cancer and other kinds of malignancies may require further investigations.

Only 1/130 (0.8%) follow-up analyses performed in 10 patients in continuous complete remission had transient expression above normal. Monitoring of SPAG6, ST18, PRAME, and XAGE1A expression in PB may predict relapse in childhood AML patients and facilitate molecular MRD monitoring in the majority of patients without a leukemia-specific target.